Lahore: Ferozsons Laboratories Limited has reported notable financial growth for the fiscal year ending June 30, 2026, in its 70th annual report, reflecting a significant move in its financial performance compared to the previous year.
The company, based in Lahore, disclosed in its unconsolidated statement of profit or loss that revenue netted at 15.76 billion rupees for 2026, up from 13.86 billion rupees in 2025. This increase showcases a substantial growth trajectory, with a very large or significant move in revenue figures. Gross profit also experienced an upward trend, reaching 6.63 billion rupees from the previous 5.72 billion rupees.
Administrative expenses rose to 930.40 million rupees, while selling and distribution expenses were recorded at 4.26 billion rupees, both indicating higher costs compared to last year. Other expenses decreased slightly to 115.26 million rupees.
According to information available from the Pakistan Stock Exchange (PSX), Ferozsons Laboratories Limited managed to achieve a profit from operations of 1.39 billion rupees, a minor move from the previous 1.38 billion rupees. Finance costs decreased, standing at 318.51 million rupees, contributing to a profit before minimum tax and income tax of 1.07 billion rupees, which marks a big move upward from the prior 923.57 million rupees.
The profit before income tax was announced at 1.04 billion rupees, up from 896.50 million rupees in 2025. After accounting for income tax expenses totaling 391.50 million rupees, the profit after taxation reached 650.90 million rupees, representing a very large or significant move from the previous year’s 528.24 million rupees.
Earnings per share also saw an increase, with basic and diluted earnings calculated at 14.97 rupees, compared to 12.15 rupees in the previous year’s report. The financial results of Ferozsons Laboratories Limited position it strongly within the market category of pharmaceuticals and healthcare, showcasing its robust performance and resilience in a competitive industry landscape.